Quantcast

Reportlinker Adds GlaxoSmithKline plc: PharmaVitae Profile

November 3, 2009

NEW YORK, Nov. 3 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

GlaxoSmithKline plc: PharmaVitae Profile

http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Introduction

This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark GlaxoSmithKline’s performance against key rivals in the prescription pharmaceutical sector

*Assess the threat posed by generic competition to GlaxoSmithKline’s core prescription pharmaceutical business

*Analyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

GlaxoSmithKline: PharmaVitae forecasts at a glance 8

Strategic insight 9

Introduction 9

Analysis of sales performance 2002-08 9

Analysis of sales performance 2008-14 10

Outlook 14

SWOT analysis 16

Strengths 17

Weaknesses 18

Opportunities 18

Threats 20

TABLE OF CONTENTS 22

Table of figures 24

Chapter 3 Quarterly news update 25

Product developments 25

Deals and alliances 27

Product deals 27

Technology deals 32

M&A activity 33

Company announcements 33

Future product milestones 35

Chapter 4 Company introduction 38

Key findings 38

Background 39

M&A history 39

Glaxo and Wellcome 39

Glaxo Wellcome 39

Smith Kline and Beecham 39

SmithKline Beecham 40

Key historical drug launches by component GSK companies 41

M&A strategy 41

R&D overview 44

Chapter 5 Company sales 46

Key findings 46

Prescription pharmaceutical sales and growth rate analysis, 2002-14 47

Product analysis 49

Product analysis, 2002-08 50

Product analysis, 2008-14 53

Therapy area analysis 56

Geographic analysis 59

Launch/core/expiry analysis 61

Explanation of launch/core/expiry analysis 61

Launch analysis, 2008-14 62

Core analysis, 2008-14 65

Expiry analysis, 2008-14 66

Launch/core/expiry configuration, 2008-14 68

Molecule type analysis 69

Externalization analysis 73

Chapter 6 Company financials 76

Key findings 76

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 77

Operating costs and profit analysis 78

Operating costs and profit analysis, 2002-08 79

Operating cost ratio and profit margin analysis, 2002-08 80

Operating cost ratio and profit margin analysis, 2008-14 81

Operating costs and profit analysis, 2008-14 82

Chapter 7 Key products and competitors 83

Overview 83

Respiratory 84

Seretide/Advair 84

Overview 84

Sales forecast 85

Beyond Advair 87

Overview 87

Sales forecast 88

Infectious diseases 89

Cervarix 89

Overview 89

Sales forecast 90

Valtrex 93

Overview 93

Sales forecast 94

Oncology 95

Tykerb/Tyverb 95

Overview 95

Sales forecast 96

Genitourinary 98

Duodart 98

Overview 98

Sales forecast 99

Central Nervous system 100

Almorexant 100

Overview 100

Sales forecast 101

Lamictal 102

Overview 102

Sales forecast 103

Imigran/Imitrex 105

Overview 105

Sales forecast 106

Endocrinology 108

Avandia 108

Overview 108

Sales forecast 109

Chapter 8 Appendix 112

R&D pipeline 112

Abbreviations 115

Exchange rates 116

About Datamonitor 117

About Datamonitor Healthcare 117

Datamonitor consulting 117

Disclaimer 119

LIST OF TABLES

Table 1: GlaxoSmithKline – PharmaVitae forecasts at a glance 8

Table 2: GlaxoSmithKline vaccine sales ($m), 2008-14 13

Table 3: GlaxoSmithKline key product developments, 2009 25

Table 4: GlaxoSmithKline product deals and alliances, 2009 27

Table 5: GlaxoSmithKline technology deals and alliances, 2009 32

Table 6: GlaxoSmithKline M&A activity, 2009 33

Table 7: GlaxoSmithKline company announcements, 2009 33

Table 8: GlaxoSmithKline future product milestones, 2009-11 35

Table 9: GlaxoSmithKline product portfolio overview ($m), 2002-08 50

Table 10: GlaxoSmithKline product portfolio overview ($m), 2008-14 53

Table 11: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2008-14 57

Table 12: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2008-14 60

Table 13: GlaxoSmithKline launch portfolio overview ($m), 2008-14 62

Table 14: GlaxoSmithKline core portfolio overview ($m), 2008-14 65

Table 15: GlaxoSmithKline expiry portfolio overview ($m), 2008-14 66

Table 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2008-14 70

Table 17: GlaxoSmithKline vaccine sales ($m), 2008-14 71

Table 18: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2008-14 74

Table 19: Total GlaxoSmithKline sales by business unit ($m), 2002-08 77

Table 20: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-08 79

Table 21: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2002-08 80

Table 22: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2008-14 81

Table 23: GlaxoSmithKline operating revenue/cost analysis ($m), 2008-14 82

Table 24: GlaxoSmithKline Key products overview 83

Table 25: Seretide/Advair: overview 84

Table 26: Seretide/Advair: sales forecast ($m), 2008-14 85

Table 27: Beyond Advair: overview 87

Table 28: Beyond Advair: sales forecast ($m), 2008-14 88

Table 29: Cervarix: overview 89

Table 30: Cervarix: sales forecast ($m), 2008-14 90

Table 31: Valtrex: overview 93

Table 32: Valtrex: sales forecast ($m), 2008-14 94

Table 33: Tykerb/Tyverb: overview 95

Table 34: Tykerb/Tyverb: sales forecast ($m), 2008-14 96

Table 35: Duodart: overview 98

Table 36: Duodart: sales forecast ($m), 2008-14 99

Table 37: Almorexant: overview 100

Table 38: Almorexant: sales forecast ($m), 2008-14 101

Table 39: Lamictal: overview 102

Table 40: Lamictal: sales forecast ($m), 2008-14 103

Table 41: Imigran/Imitrex: overview 105

Table 42: Imigran/Imitrex: sales forecast ($m), 2008-14 106

Table 43: Avandia: overview 108

Table 44: Avandia: sales forecast ($m), 2008-14 109

Table 45: GlaxoSmithKline’s R&D pipeline (Phase I-registration) 112

Table 46: Exchange rates, 2009 116

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: GlaxoSmit6thKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: GlaxoSmithKline’s financial performance ($m), 2002-14 7

Figure 4: GlaxoSmithKline launch/core/expiry configuration ($m), 2002-08 9

Figure 5: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 10

Figure 6: GlaxoSmithKline prescription pharmaceutical sales growth by molecule type ($m), 2008-14 12

Figure 7: GlaxoSmithKline SWOT analysis 16

Figure 8: M&A/divestment history 40

Figure 9: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 47

Figure 10: Key product sales ($m), 2002-14 49

Figure 11: GlaxoSmithKline key sales growth drivers and resistors ($m), 2002-08 52

Figure 12: GlaxoSmithKline key sales growth drivers and resistors ($m), 2008-14 55

Figure 13: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2002-14 56

Figure 14: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2002-14 59

Figure 15: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 68

Figure 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2002-14 69

Figure 17: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2002-14 73

Figure 18: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-14 78

To order this report:

GlaxoSmithKline plc: PharmaVitae Profile

http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus